AMYLO
LIVE

Serial Number

79401325

Owner

BeauBrain Healthcare

Attorney

April L. Besl

Filing Date

May 30, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AMYLO Trademark

Serial Number: 79401325 • Registration: 7979697

AMYLO is a trademark filed by BeauBrain Healthcare on May 30, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

BeauBrain Healthcare (2 trademarks)

2F, 314 Hakdong-ro,

Entity Type: 03

Trademark Details

Filing Date

May 30, 2024

Registration Date

October 14, 2025

Published for Opposition

August 26, 2025

Goods & Services

Software as a medical device (SaMD), downloadable, for treating Alzheimer's disease; downloadable computer software for data processing in the field of Alzheimer's disease; downloadable computer software for database management in the field of Alzheimer's disease; downloadable software for processing digital images in the field of Alzheimer's disease; downloadable software for processing images, graphics and text in the field of Alzheimer's disease; downloadable computer software for diagnosing diseases, namely, Alzheimer's disease, for medical purposes; downloadable computer software for use in medical decision support systems in the field of Alzheimer's disease; data processing apparatus for use in the field of Alzheimer's disease; downloadable image files of human brains for use in the field of Alzheimer's disease; downloadable electronic documents in the field of image processing for use in treatment of Alzheimer's disease

Medical apparatus for the diagnosis of cerebrovascular diseases; medical apparatus for the diagnosis of neurological diseases; medical apparatus and instruments for predicting, diagnosing, and treating Alzheimer's disease; apparatus for carrying-out diagnostic tests for Alzheimer's disease for medical purposes; diagnostic apparatus for diagnosing Alzheimer's disease for medical purposes; radiological diagnostic imaging apparatus, namely, Positron Emission Tomography (PET), Computed Tomography (CT), and Magnetic Resonance Imager (MRI) for medical purposes relating to diagnosis and treatment of Alzheimer's disease; diagnostic measuring apparatus for medical use for measuring beta-amyloid plaque for use in the diagnosis and tratment of Alzheimer's disease; medical apparatus and instruments, namely, apparatus for medical diagnostic testing for use in the fields of clinical diagnosis of Alzheimer's disease; automatic analyzers in the nature of PET, CT, and MRI for medical diagnosis of Alzheimer's disease; electromedical diagnostic instruments for diagnosing Alzheimer's disease

Software as a service (SAAS) services featuring software for image processing for use in diagnosis and treatment of Alzheimer's disease; technological and scientific remote monitoring services relating to the function of medical diagnostic devices in the field of Alzheimer's disease; research and development of medical apparatus and instruments for use in Alzheimer's disease medical diagnostic testing for others; research and development of medical equipment for use in Alzheimer's disease medical diagnostic testing; research and development of medical devices for use in Alzheimer's disease medical diagnostic testing; providing technological support services, namely, providing technical advice related to the research and development of medical diagnostic instruments for use in diagnosing Alzheimer's disease; technological and scientific monitoring services relating to the function of Alzheimer's disease medical diagnostic instruments; technology consultation in the field of artificial intelligence for use in the field of diagnosing and treating Alzheimer's disease; research and development of diagnostic apparatus for use in diagnosing Alzheimer's disease; computer aided diagnostic testing services for use in diagnosing Alzheimer's disease

Providing medical advice in the field of geriatrics relating to Alzheimer's disease; medical analysis for the diagnosis and treatment of persons with Alzheimer's disease; health care services for treating Alzheimer's disease; remote monitoring of medical data for medical diagnosis and treatment of Alzheimer's disease; medical analysis services for the diagnosis of Alzheimer's disease; medical diagnostic services for Alzheimer's disease; mental health screening services relating to Alzheimer's disease; medical testing services relating to the diagnosis and treatment of Alzheimer's disease; performing diagnosis of Alzheimer's disease; medical advisory services relating to the treatment of degenerative diseases, namely, Alzheimer's disease

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 14, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 28, 2026 FICS
FINAL DISPOSITION PROCESSED
Apr 28, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 15, 2026 OPNX
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 14, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 31, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 31, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 18, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 18, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 18, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 18, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 27, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 27, 2025 TROA
REFUSAL PROCESSED BY IB
Jan 17, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 27, 2024 RFCS
REFUSAL PROCESSED BY MPU
Dec 27, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 13, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 12, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 12, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 6, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 6, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 1, 2024 REPR